SCYX vs GILD vs MRK vs PFE

For growth investors, SCYNEXIS, Inc.

(SCYX) is the stronger pick with 449. 9% revenue growth year-over-year, versus -1. 6% for Pfizer Inc. (PFE). Merck & Co. , Inc. (MRK) offers the better valuation at 15. 4x trailing P/E (21. 7x forward), making it the more compelling value choice. Analysts rate Gilead Sciences, Inc. (GILD) a "Buy" — based on 58 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Merck & Co.

, Inc. (MRK) is the cheapest at 15. 4x versus Gilead Sciences, Inc. at 19. 8x. On forward P/E, Pfizer Inc. is actually cheaper at 8. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Gilead Sciences, Inc. wins at 0. 12x versus Merck & Co. , Inc. 's 1. 02x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Gilead Sciences, Inc.

(GILD) delivered a total return of +124. 2%, compared to -86. 1% for SCYNEXIS, Inc. (SCYX). Over 10 years, the gap is even starker: MRK returned +164. 7% versus SCYX's -97. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Merck & Co.

, Inc. (MRK) is the lower-risk stock at 0. 45β versus SCYNEXIS, Inc. 's 0. 70β — meaning SCYX is approximately 54% more volatile than MRK relative to the S&P 500. On balance sheet safety, SCYNEXIS, Inc. (SCYX) carries a lower debt/equity ratio of 4% versus 109% for Gilead Sciences, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), SCYNEXIS, Inc.

(SCYX) is pulling ahead at 449. 9% versus -1. 6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: Gilead Sciences, Inc. grew EPS 1684% year-over-year, compared to -3. 5% for Pfizer Inc.. Over a 3-year CAGR, SCYX leads at 59. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Gilead Sciences, Inc.

(GILD) is the more profitable company, earning 28. 9% net margin versus -41. 8% for SCYNEXIS, Inc. — meaning it keeps 28. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GILD leads at 40. 1% versus -78. 0% for SCYX. At the gross margin level — before operating expenses — GILD leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Gilead Sciences, Inc. (GILD) is the more undervalued stock at a PEG of 0. 12x versus Merck & Co. , Inc. 's 1. 02x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Pfizer Inc. (PFE) trades at 8. 7x forward P/E versus 21. 7x for Merck & Co. , Inc. — 13. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GILD: 20. 8% to $162. 00.

In this comparison, PFE (6.

5% yield), MRK (2. 9% yield), GILD (2. 4% yield) pay a dividend. SCYX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Merck & Co.

, Inc. (MRK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 45), 2. 9% yield, +164. 7% 10Y return). Both have compounded well over 10 years (MRK: +164. 7%, SCYX: -97. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SCYX is a small-cap high-growth stock; GILD is a mid-cap quality compounder stock; MRK is a large-cap deep-value stock; PFE is a mid-cap income-oriented stock. GILD, MRK, PFE pay a dividend while SCYX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.